Product Information
BUPROPION HCL XL 150 MG TABLET is a generic product labeled by Vitruvias Therapeutics Inc., priced at $0.0785 per EA under NDC 69680015790. Its NADAC has been published 65 times since Jul 9, 2025.
FDA first approved this application on Aug 21, 2017. Its Orange Book therapeutic-equivalence code is AB3 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Vitruvias Therapeutics Inc.NDC
69680015790
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
BUPROPION HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA208652FDA Approved
8/21/2017
TE Code
AB3
On Market Since
4/10/2023
Pharmacological Classes
Price Statistics
The NADAC for BUPROPION HCL XL 150 MG TABLET has been published 65 times since Jul 9, 2025, and over the history we have for it it has declined 24.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0785 per EA |
|---|---|
| All-time high | $0.1042 (Jul 16, 2025) |
| All-time low | $0.0770 (Apr 22, 2026) |
| 52-week high | $0.0996 |
| 52-week low | $0.0770 |
| Median price | $0.0792 |
| Average price | $0.0869 |
| Largest weekly change | -8.4% (Feb 18, 2026) |
| Weeks tracked | 65 |
| Tracking since | Jul 9, 2025 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Vitruvias Therapeutics Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Bupropion hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminoketone class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUPROPION HCL XL 150 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BUPROPION HCL XL 150 MG TABLET, manufactured by Vitruvias Therapeutics Inc., is $0.0785 per EA (NDC 69680015790), effective Sep 30, 2026.
How has the price of BUPROPION HCL XL 150 MG TABLET changed over time?
Over the history we have for it, the NADAC for BUPROPION HCL XL 150 MG TABLET has declined 24.7%. It has been tracked across 65 weekly CMS publications since Jul 9, 2025.
What are the highest and lowest recorded NADAC prices for BUPROPION HCL XL 150 MG TABLET?
Since Jul 9, 2025, the NADAC for BUPROPION HCL XL 150 MG TABLET has ranged from a low of $0.0770 (Apr 22, 2026) to a high of $0.1042 (Jul 16, 2025), with a median of $0.0792 per EA.
Are there cheaper alternatives to BUPROPION HCL XL 150 MG TABLET?
7 manufacturers publish a NADAC-priced product with the same active ingredient and strength as BUPROPION HCL XL 150 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures BUPROPION HCL XL 150 MG TABLET?
BUPROPION HCL XL 150 MG TABLET (NDC 69680015790) is labeled by Vitruvias Therapeutics Inc., and CMS classifies it as a generic product.